Pfizer ( PFE) ($24.58 vs. $25.43 on Oct. 29): When the stock market reopened Oct. 31 this stock traded up to my quarterly risky level at $25.74, where profits should have been taken. The stock is now below its 50-day SMA at $24.79. The weekly chart profile is negative with the five-week MMA at $24.78. My semiannual value level is $20.51 with the quarterly pivot at $25.74. Barrick Gold ( ABX) ($35.08 vs. $39.18 on Oct. 29): Tested its 200-day SMA at $40.69 Wednesday for an opportunity to sell strength. I do not show a value level but my semiannual pivot is $37.60. Teva Pharmaceuticals ( TEVA) ($41.14 vs. $40.39 on Oct. 29): The stock is trading between its 50-day SMA at $40.40 and its 200-day SMA at $41.80. Exxon Mobil ( XOM) ($90.63 vs. $90.62 on Oct. 29): Weakness on Monday held my monthly pivot at $89.78 with the close just below the 50-day SMA at $90.77. The weekly chart shifts to negative on a close this week below the five-week MMA at $90.62. This week's risky level is $92.87. Newmont Mining ( NEM) ($48.39 vs. $53.07 on Oct. 29): My annual pivot and semiannual risky level at $53.89 and $54.88 last Wednesday where investors and traders were advised to sell strength. The stock ended last week below my quarterly pivot at $49.36. My new monthly value level is $41.67. Starbucks ( SBUX) ($51.01 vs. $45.87 on Oct. 29): Matched revenue estimates and gave an optimistic outlook. The stock popped above my semiannual pivot at $49.81 on Friday to a test of its 200-day SMA at $51.37. My annual value level is $44.25 with a monthly risky level at $53.41. Chevron ( CVX) ($109.19 vs. $111.18 on Oct. 29): Traded down from $111.94 last Wednesday to a test of its 200-day SMA at $107.57 on Friday. My monthly value level is $107.67 with a weekly risky level at $113.22. At the time of publication the author held no positions in any of the stocks mentioned. Follow @Suttmeier This article is commentary by an independent contributor, separate from TheStreet's regular news coverage.